HSP70-ATTO 680
Compared with the conventional antibody, sdAb presents great advantages in biological therapeutic and diagnostic development. Our one-stop discovery platforms enable the novel sdAb discovery as research tool, therapeutic candidate, or diagnostic reagent. From the target identification to the final IND-enabling, we have the capability to enable you to free up your time for core work and project. Furthermore, the subsequent sdAb development and characterization services can further meet the diverse needs of our customers.